• Arcturus scheduled a virtual event for Sept. 23, 2026 to present Phase 2 data for ARCT-810 in OTC deficiency.
• Results have not been presented yet; a summary is slated for release ahead of the presentation.
• Update will also cover the company’s mRNA liver therapeutics platform, signaling continued investment in rare-disease liver programs.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arcturus Therapeutics Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202609180900BIZWIRE_USPR_____20260918_BW208396) on September 18, 2026, and is solely responsible for the information contained therein.